Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-label, Multicenter, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of EXS73565 in Participants With Relapsed or Refractory B-cell Malignancies

NCT06980116 is registered in ClinicalTrials.gov with Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. as lead sponsor.

NCT NCT06980116
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06980116 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-label, Multicenter, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of EXS73565 in Participants With Relapsed or Refractory B-cell Malignancies
Lead sponsor
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
March 31, 2025
Completion date
December 31, 2028
Enrollment
85 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia/small lymphocytic lymphoma (cll/sll), diffuse-large b-cell lymphoma (dlbcl), follicular lymphoma (fl), mantle cell lymphoma (mcl), marginal zone lymphoma (mzl), relapsed or refractory b-cell malignancies, waldenstrom's macroglobulinemia (wm)